Figure 1. Serotonin and GOA-1 Signaling in cat-1 and dgk-1 Mutants
Behavioral assays and drug treatments and transgenic animals were as described in the Experimental Procedures. Drug treatments are indicated by the legends. (A) Locomotion of cat-1(e1111) was partially resistant to fluoxetine but not to serotonin, whereas locomotion of dgk-1(nu199) was partially resistant to both. Animals (nuIs45) expressing gfp::dgk-1 (gfp-d) or a heat shock-promoted dgk1a cDNA (hsdgk) had slower locomotion rates than wild type. (B) Egg laying of cat-1(e1111) mutants was partially resistant to fluoxetine but was sensitive to serotonin, whereas that of dgk-1(nu199) mutants was fully sensitive to both. (C) Effects of GOA-1 activity on locomotion. GOA-1 signaling was increased by expressing transgenes containing wild-type GOA-1 or GOA-1(Q205L). In cat-1(e1111) mutants, GOA-1 inhibited locomotion while the effect of GOA-1 activity on locomotion was significantly reduced in dgk-1(nu199) mutants. Errors indicate the standard error of the mean. Asterisk indicates animals expressing GOA-1(Q205L) whose standard errors were less than 0.12.
shown). In addition to these phenotypes, homozygous resistant to fluoxetine but remained sensitive to exogenous serotonin ( Figures 1A and 1B) . Therefore, cat-1 dgk-1 mutants also tend to form large clumps of animals at the edges of the bacterial lawn (data not shown), mutants fit the pharmacological profile predicted for a defect in the serotonergic neurons. Similarly, cat-4 which has been termed the bordering phenotype (de Bono and Bargmann, 1998). The bordering phenotype mutants, which have abnormally low levels of endogenous serotonin (Desai et al., 1988) , also fit the profile for occurs in mutants lacking a putative neuropeptide receptor (NPR-1) (de Bono and Bargmann, 1998) but is a defect in the serotonergic neurons ( Figure 1B ). By contrast, the hyperactive locomotion of dgk-1 munot seen in other serotonin-defective mutants (e.g., cat-1 and cat-4), suggesting that the dgk-1 gene acts both in tants was partially resistant to both serotonin and fluoxetine ( Figure 1A ). These results suggested that dgk-1 serotonin and in peptidergic signaling pathways. acts in the serotonin target tissues. Interestingly, not all serotonin targets required dgk-1, since the egg laying dgk-1 Mutations Cause Defects in Serotonin Target Cells of dgk-1 mutants was still stimulated by serotonin (Figure 1B) . Thus, dgk-1 is required for serotonin inhibition The behavioral deficits observed in dgk-1 mutants could reflect impaired function of either the serotonergic neuof locomotion but not for serotonin stimulation of egg laying. rons or the serotonin target cells. In principle, one can distinguish between these possibilities by testing the response of mutant animals to exogenous serotonin or to fluoxetine, which exaggerates the effects of endoge-
dgk-1 Encodes a Diacylglycerol Kinase
We mapped the dgk-1 gene to a small region on the left nous serotonin by inhibiting plasma membrane serotonin reuptake pumps. A normal response to fluoxetine arm of the X chromosome between aex-3 and unc-1. A cosmid clone (C06G11) from this region corrected the requires function of both the serotonergic neurons and the serotonin-responding cells, whereas a normal relocomotion and egg laying defects of dgk-1 mutants in transgenic animals (data not shown). All five dgk-1 alsponse to serotonin only requires the latter (Trent et al., 1983; Weinshenker et al., 1995) ; therefore, responleles corresponded to mutations in a gene (C09E10.2, accession U49946), which encodes a protein that is 38% siveness to these drugs allowed us to distinguish mutants with defects in these two cell types.
identical to a human diacylglycerol (DAG) kinase, DGK (Houssa et al., 1997) (Figures 2A and 2B ). Four dgk-1 To confirm the validity of this approach, we tested whether responsiveness to these drugs correctly prealleles caused very similar behavioral defects and potentially correspond to severe loss-of-function mutadicts the site of cat-1 function. The cat-1 VMAT is expressed in serotonergic and dopaminergic neurons, tions. The alleles nu62 and n892 are nonsense mutations, while nu199 and n2949 disrupt donor and acwhere it mediates transport of these monoamines into synaptic vesicles (Duerr et al., 1999) . The locomotion ceptor splicing consensus signals in intron 7, all of which should reduce DGK-1 activity. A fifth allele (nu76) and egg laying behaviors of cat-1 mutants were partially corresponds to a missense mutation (A247V) in a nonexpression vector, restored normal locomotion rates, demonstrating that DGK-1a is a functional form of dgk-1 catalytic domain and causes less severe hyperactivity. Expression of a full-length gfp::dgk-1 translational fu-DAG kinase and can act in adults ( Figure 1A ). DAG kinases are encoded by a large gene family that sion construct (Figure 2A ) in dgk-1 mutants reduced the locomotion rate below that of wild-type animals and has been conserved across phylogeny. The genome database predicts at least five distinct C. elegans DAG restored responsiveness to exogenous serotonin and fluoxetine ( Figure 1A) . These results demonstrated kinase isoforms, and twelve mammalian isoforms have been described (Topham and Prescott, 1999) . All DAG that the gene identified by these mutations encodes a putative DAG kinase. Furthermore, since wild-type kinases share a common enzymatic activity, phosphorylation of DAG to produce phosphatidic acid. To confirm transgenes rescued dgk-1 mutant phenotypes, these results also suggest that dgk-1 alleles reduce gene acthat dgk-1 encodes a catalytically active DAG kinase, we expressed full-length DGK-1 cDNAs in HEK293 cells tivity.
We isolated full-length DGK-1 cDNA clones and deter-( Figure 2C ). Cells transfected with the DGK-1 expression construct produced significantly more DAG kinase acmined their sequence ( Figure 2B ). The predicted DGK-1 protein contains 950 amino acids, which share several tivity than nontransfected cells, and this kinase was active with two different diglyceride substrates. salient features with human DGK. Like DGK, DGK-1 has three amino terminal cysteine-rich domains (which are thought to bind DAG), a potential pleckstrin homolcat-1 VMAT Acts Upstream of goa-1 G␣ o Prior results suggested that goa-1 G␣ o mediates many ogy domain, and a catalytic domain. Although it is highly expressed in the brain, the function of DGK in neural of the effects of serotonin Sé galat et al., 1995) . The similarity of the behavioral defects signaling has not been determined. Two alternatively spliced forms (DGK-1a and DGK-1b) were detected, observed in cat-1 and dgk-1 mutants to those observed in goa-1 mutants suggested that these genes are part which differ by three amino acids in a region of unknown function (Figure 2A ). Transient expression of the DGK-1a of a common signaling pathway. To further examine the role of GOA-1 in serotonin signaling, we tested whether cDNA in adult dgk-1 mutants, utilizing a heat shock Figure 1C and Table 1 4B ). In addition to the neurons, the GFP reporters were also expressed in the excretory canals ( Figure 4B ). The GFP::DGK-1 fusion protein was localized to an organellar structure in the cell bodies of neurons and appeared to be diffusely distributed throughout the cell bodies and axons ( Figure 4C ). Thus, goa-1 G␣ o and dgk-1 DAG kinase were both ubiquitously expressed in the worm nervous system.
Given their expression patterns, we wondered if goa-1 G␣ o and dgk-1 DAG kinase act in the ventral cord motor to homozygous dgk-1 mutants (Table 2, line 17). These results suggest that goa-1 G␣ o and dgk-1 DAG kinase act in motor neurons, directly or indirectly regulating suggest that serotonin regulates synaptic transmission release of acetylcholine at neuromuscular junctions. by inhibiting release of acetylcholine at neuromuscular Given their broad expression patterns, these genes junctions.
probably act in many other neural circuits as well.
goa-1 G␣ o Regulates the Abundance of UNC-13 The Effects of Serotonin on Acetylcholine Release
at Nerve Terminals Require goa-1 G␣ o and dgk-1 DAG Kinase
The dgk-1 DAG kinase phosphorylates DAG, converting Since goa-1 G␣ o and dgk-1 DAG kinase are required it into phosphatidic acid ( Figure 2C ). Therefore, eliminatfor serotonin inhibition of locomotion ( Figure 1A) , we ing the dgk-1 DAG kinase is predicted to cause an inwondered whether these genes are also required for creased abundance of DAG, which could explain the serotonin inhibition of acetylcholine release. Serotonin aldicarb hypersensitivity caused by dgk-1 mutations. treatment did not cause aldicarb resistance in mutants Consistent with this idea, we showed that treating wildlacking either goa-1 G␣ o or dgk-1 DAG kinase (Table 2, type animals with phorbol esters induced hypersensitivlines 7 and 14). In fact, homozygous goa-1 G␣ o (line 6) ity to aldicarb (Table 2 , line 3), suggesting an increased or dgk-1 DAG kinase (line 13) mutants were hypersensirelease of acetylcholine. Since dgk-1 mutations also tive to aldicarb compared to wild-type controls (line 1), prevented goa-1 G␣ o induced paralysis, we wondered consistent with an increased release of acetylcholine.
whether phorbol ester treatment would block goa-1 G␣ o Transient expression of either GOA-1(Q205L) or DGK-1a inhibition of acetylcholine release. Consistent with this idea, we found that phorbol ester treatment produced (utilizing a heat shock expression vector) made animals Figure 5A ; Table 3 ). The distribution of UNCbind to C1 domains) have been shown to promote membrane association of several DAG-binding proteins (Betz 13S::GFP was not significantly altered in mutants lacking dgk-1 DAG kinase ( Figure 5E ; Figure 5C ; Table 3 ). Mutants that lack endogenous serotonin (e.g., cat-4) and wild-type animals abundance of UNC-13 at nerve terminals.
To test this idea, we constructed an expression vector treated with the serotonin antagonist methiothepin had a slight increase in the number of UNC-13S::GFP puncta for the short form of UNC-13 (UNC-13S, accession 3881735), which contains 1293 amino acids including ( Figure 5B and Table 3 ). To test the importance of DAG under the control of the unc-13S promoter. In animals coexpressing these two constructs, we see a clear colocalization of the UNC-13S::YFP punctate structures with clusters of SNB-1::CFP ( Figure 5F ). In homozygous goa-1 G␣ o mutants, 81% of the SNB-1::CFP puncta at motor neuron nerve terminals colocalized with a corresponding UNC-13S::YFP punctum (n ϭ 162 SNB-1::CFP puncta and nine animals). These results confirm that UNC-13S accumulates at acetylcholine release sites of motor neurons in mutants lacking goa-1 G␣ o . Our data are most consistent with the model that serotonin and GOA-1 specifically regulate DAG levels at nerve terminals and, as a consequence control, the abundance of UNC-13 at acetylcholine release sites.
Discussion
We showed that serotonin modulates C. elegans locomotion by inhibiting release of acetylcholine at neuromuscular junctions. The effects of serotonin on acetylcholine release require goa-1 G␣ o and dgk-1 DAG kinase, which act in the ventral cord motor neurons. Finally, we showed that goa-1 G␣ o regulates the abundance of the presynaptic protein UNC-13S at motor neuron nerve terminals. Based on these results, we propose a model for presynaptic inhibition by serotonin ( Figure  6 ), which suggests that serotonin directly regulates some aspect of synaptic vesicle exocytosis or recycling, at least in this case. 
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release (as evidenced by epistasis experiments with cat-1 VMAT mutations). Second, GOA-1 is required for serotonin-mediated inhibition of synaptic transmission. binding for UNC-13S localization, we expressed a mutant form of UNC-13S, H173K, in which we altered a
Third, both serotonin and GOA-1 regulate the localization of UNC-13 at motor neuron nerve terminals, sugconserved histidine residue in the C1 domain that is required for binding to phorbol esters (Betz et al., 1998).
gesting that both act directly at the ventral cord neuromuscular junctions. Unlike the wild-type protein, UNC-13S(H173K)::GFP remained diffusely distributed in goa-1 G␣ o mutants (Fig- On the other hand, it is likely that GOA-1 also plays an important role in other neurotransmitter pathways. ure 5D and Table 3 ). Thus, goa-1 G␣ o regulates the distribution of UNC-13S::GFP in the ventral nerve cord, and
The effects of GOA-1 on egg laying cannot be explained by a defect in serotonin signaling. Serotonin is an excitthis effect depends upon the ability of UNC-13S to bind to DAG. atory neurotransmitter acting at the egg laying neuromuscular junctions, yet goa-1 G␣ o inhibits egg laying To determine if the punctate structures containing UNC-13S::GFP corresponded to acetylcholine release Sé galat et al., 1995) . In addition, the behavioral defects observed in goa-1 mutants are sites at neuromuscular junctions, we conducted double labeling experiments. Neuromuscular junctions were lamuch more severe than those seen in cat-1 mutants. These results suggest that GOA-1 also mediates the beled by expressing a cyan fluorescent protein tagged synaptobrevin construct (SNB-1::CFP) in motor neurons effects of other unidentified neuromodulators. Consistent with this idea, we found a substantially larger num- (Rongo et al., 1998) . UNC-13S was visualized by expressing a yellow fluorescent protein tagged UNC-13S ber of UNC-13S::GFP containing puncta in the ventral rather than locally at neuromuscular junctions. For example, since DGK-1::GFP appears to be uniformly distributed throughout the ventral cord, then it is likely that DAG is elevated throughout the ventral cord in dgk-1 mutants. Although DAG is diffusely distributed in these cases, its increased levels at release sites would nonetheless stimulate acetylcholine release. By contrast, DAG could be selectively elevated at neuromuscular junctions in goa-1 mutants, leading to the punctate distribution of UNC-13S::GFP. Alternatively, localization of UNC-13S could require the coincidence of two distinct signals. For example, since it contains both C1 and two C2 domains, it is possible that UNC-13S localization is dependent on both DAG and calcium. In this scenario, dgk-1 DAG kinase mutants would only elevate DAG levels and, hence, would not alter UNC-13S distribution. By contrast, if goa-1 G␣ o regulates both DAG and calcium levels, then changes in goa-1 G␣ o activity would alter the distribution of UNC-13S. Behaviors were assayed 2 hr after exposure to drugs. For locomowere isolated as hyperactive mutants following mutagenesis with tion rates, each animal was assayed three times for 1 min each. At ethylmethane sulfonate. cat-1(e1111) was isolated previously in a least ten animals were tested in all cases. For animals expressing screen for mutations that reduce the abundance of endogenous GOA-1(Q205L) (syIs17), behaviors were analyzed 1 hr after a 30 min dopamine (Sulston et al., 1975) . The nu90 allele is a missense mutaheat shock at 33ЊC. tion in the cat-1 VMAT (A406V). Two dgk-1 alleles were provided by Sensitivity to aldicarb and levamisole was determined by analyz-M. Finney (n892) and E. Sawin (n2949). All of these alleles have a ing the onset of paralysis following treatment with either 1 mM purely recessive pattern of heredity. Allelism was determined by aldicarb (Chem Services) or 100 M levamisole (Sigma). Locomotion complementation tests and by meiotic mapping.
was assessed by prodding animals with a platinum wire every 10 min following exposure to drug. Where indicated, animals were prePositional Cloning of dgk-1 treated (for 2 hr) prior to aldicarb treatment together with a second We mapped the dgk-1 gene to a small region on the left arm of the drug, as follows: with 3.8 mg/ml serotonin creatine sulfate; with 2 X chromosome between aex-3 and unc-1. A cosmid clone (C06G11) g/ml Phorbol 12-myristate 13-acetate (PMA); with 1 mg/ml ketanfrom this region corrected the locomotion and egg laying defects serin or 50 g/ml methiothepin or 1 mg/ml haloperidol; with transient of dgk-1 mutants in transgenic animals (data not shown). Sequence expression of GOA-1(Q205L) or DGK-1a from heat shock expression changes in mutant alleles were determined by amplifying exons and vectors for 30 min at 33ЊC. For each experiment, 25 animals were exon/intron boundaries from mutant strains and direct sequencing tested blind with respect to the genotype or drug treatment. Each of the amplified products by cycle sequencing. experiment was repeated at least three times.
Diacylglycerol Kinase Assays Transgenes and Germline Transformation
HEK 293 cells were transfected with 1 g of either GW1, KP#137, Plasmids were constructed by standard techniques, and sequences KP#143, or FLAG DGK (a gift of S. Prescott) using lipofectamine were verified where appropriate; full details are available on request.
(GIBCO). DAG kinase activity in 7.5 g of cell extract was assayed Transgenic strains were isolated by microinjecting various plasmids 48 hr after transfection, essentially as described (Tolias et al., 1998) . (typically at either 50 or 100 ng/l) using ttx-3::gfp (a gift of O. Hobert) Phosphorylated lipids were quantified by scintillation counting. as a marker. Plasmids and transgenic strains were constructed as follows.
DGK-1 Constructs
Fluorescence Microscopy GFP containing strains were mounted on agarose pads and viewed KP#174, a rescuing full-length gfp::dgk-1 fusion gene, contains GFP fused in-frame at the amino terminus. nuIs45 contains an integrated on an Aviovert microscopes, using a Planapo 63ϫ (NA ϭ 1.4), Planneo 40ϫ (NA ϭ 1.3) (Figure 4B ), or Planneo 10ϫ (NA ϭ 0.3) ( Figure 4A ) version of the KP#174 transgene. KP#329, a dgk-1::gfp fusion construct, contains GFP fused in-frame at a unique XhoI site in exon objective. Images were captured with a Hamamatsu ORCA digital camera. Digital images were processed to remove out of focus 8 of dgk-1. nuIs15 contains an integrated version of the KP#329 transgene. KP#137 and KP#143 are full-length (2.85 kb) DGK-1a light and to give maximum intensity projections of a z series, using Metamorph 4.0 image processing software (Universal Imaging Corand DGK-1b cDNA clones in the cytomegalovirus expression vector GW1 (Choi et al., 1991). KP#207 is a heat shock-promoted DGK-1a poration). UNC-13 puncta were thresholded using Metamorph and 
